Pulmonx Q2 Revenue Up 21%, But Net Loss Widens to $25.3M
Ticker: LUNG · Form: 10-Q · Filed: Aug 1, 2025 · CIK: 1127537
| Field | Detail |
|---|---|
| Company | Pulmonx Corp (LUNG) |
| Form Type | 10-Q |
| Filed Date | Aug 1, 2025 |
| Risk Level | high |
| Sentiment | mixed |
Sentiment: mixed
Topics: Medical Devices, Biotechnology, Respiratory Health, Earnings Report, Net Loss, Revenue Growth, Cash Burn
Related Tickers: LUNG
TL;DR
LUNG's revenue growth is promising, but the escalating losses mean it's still a speculative bet on future profitability.
AI Summary
Pulmonx Corp reported a net loss of $25.3 million for the three months ended June 30, 2025, a significant increase from the $20.1 million net loss in the prior-year quarter. Revenue for the second quarter of 2025 reached $45.9 million, demonstrating a 21% increase compared to $37.9 million in the second quarter of 2024. The company's accumulated deficit grew to $459.0 million as of June 30, 2025, up from $433.7 million at March 31, 2025, indicating continued operational losses. Strategic outlook includes continued investment in research and development, with R&D expenses totaling $18.9 million for the quarter, up from $15.5 million in the same period last year. Key risks include the company's reliance on the Zephyr Endobronchial Valve for revenue and the ongoing need for significant capital to fund operations, as evidenced by the accumulated deficit. The company's cash and cash equivalents decreased to $189.0 million as of June 30, 2025, from $210.0 million at December 31, 2024, highlighting cash burn. Despite revenue growth, the expanding net loss and accumulated deficit suggest challenges in achieving profitability.
Why It Matters
Pulmonx's continued revenue growth, up 21% to $45.9 million, signals strong market adoption for its Zephyr Endobronchial Valve, which is crucial for investors assessing its competitive position against other medical device companies in the respiratory space. However, the widening net loss to $25.3 million and an accumulated deficit of $459.0 million raise concerns about the company's path to profitability and its long-term financial sustainability for shareholders. Employees and customers benefit from the company's innovation in treating severe emphysema, but the financial performance could impact future investment in product development and market expansion. The broader market will watch if Pulmonx can translate its sales momentum into a sustainable business model, especially given the competitive landscape in medical devices.
Risk Assessment
Risk Level: high — The risk level is high due to the company's persistent and widening net losses, reaching $25.3 million in Q2 2025, and a substantial accumulated deficit of $459.0 million as of June 30, 2025. This indicates a significant cash burn and a continued reliance on external financing, with cash and cash equivalents decreasing to $189.0 million from $210.0 million in six months.
Analyst Insight
Investors should monitor Pulmonx's cash burn rate and path to profitability closely. While revenue growth is positive, the increasing net losses suggest caution; consider if the market adoption of the Zephyr valve can outpace operational expenses in the coming quarters before making significant investments.
Financial Highlights
- revenue
- $45.9M
- net Income
- -$25.3M
- cash Position
- $189.0M
- revenue Growth
- +21%
Key Numbers
- $45.9M — Q2 2025 Revenue (Increased 21% from $37.9M in Q2 2024)
- -$25.3M — Q2 2025 Net Loss (Widened from -$20.1M in Q2 2024)
- $459.0M — Accumulated Deficit (Increased from $433.7M at March 31, 2025)
- $189.0M — Cash and Cash Equivalents (Decreased from $210.0M at December 31, 2024)
- 21% — Revenue Growth (Year-over-year increase in Q2 2025 revenue)
Key Players & Entities
- Pulmonx Corp (company) — filer of the 10-Q
- $25.3 million (dollar_amount) — net loss for Q2 2025
- $20.1 million (dollar_amount) — net loss for Q2 2024
- $45.9 million (dollar_amount) — revenue for Q2 2025
- $37.9 million (dollar_amount) — revenue for Q2 2024
- $459.0 million (dollar_amount) — accumulated deficit as of June 30, 2025
- $433.7 million (dollar_amount) — accumulated deficit as of March 31, 2025
- $18.9 million (dollar_amount) — R&D expenses for Q2 2025
- $15.5 million (dollar_amount) — R&D expenses for Q2 2024
- Zephyr Endobronchial Valve (company) — Pulmonx's primary product
FAQ
What were Pulmonx Corp's key financial results for Q2 2025?
Pulmonx Corp reported revenue of $45.9 million for the three months ended June 30, 2025, representing a 21% increase from $37.9 million in the prior-year quarter. However, the company's net loss widened to $25.3 million, compared to a net loss of $20.1 million in Q2 2024.
How has Pulmonx's accumulated deficit changed?
Pulmonx's accumulated deficit increased to $459.0 million as of June 30, 2025, up from $433.7 million at March 31, 2025. This indicates a continued trend of operational losses accumulating over time.
What is the strategic outlook for Pulmonx Corp based on this 10-Q?
The strategic outlook for Pulmonx Corp involves continued investment in research and development, with R&D expenses increasing to $18.9 million in Q2 2025 from $15.5 million in Q2 2024. The company aims to drive market adoption of its Zephyr Endobronchial Valve.
What are the primary risks highlighted in Pulmonx's 10-Q filing?
Primary risks include the company's widening net losses, which reached $25.3 million in Q2 2025, and its substantial accumulated deficit of $459.0 million. This indicates a significant cash burn and ongoing need for capital to fund operations, as evidenced by the decrease in cash and cash equivalents to $189.0 million.
How does Pulmonx's cash position look as of June 30, 2025?
As of June 30, 2025, Pulmonx Corp's cash and cash equivalents stood at $189.0 million. This represents a decrease from $210.0 million reported at December 31, 2024, indicating a burn rate of $21.0 million over six months.
What impact does the widening net loss have on Pulmonx investors?
The widening net loss to $25.3 million for Q2 2025 signals to investors that Pulmonx is not yet profitable, despite revenue growth. This could lead to concerns about the company's long-term financial viability and potential need for future capital raises, which could dilute existing shareholder value.
What product is central to Pulmonx Corp's revenue generation?
The Zephyr Endobronchial Valve is central to Pulmonx Corp's revenue generation. The company's financial performance is heavily reliant on the continued market adoption and sales growth of this specific medical device for severe emphysema.
Did Pulmonx Corp experience any significant changes in equity during Q2 2025?
The 10-Q shows changes in equity accounts, including common stock and additional paid-in capital, reflecting activities such as stock-based compensation and potential equity issuances. The accumulated deficit increased from $433.7 million at March 31, 2025, to $459.0 million at June 30, 2025.
How does Pulmonx's Q2 2025 performance compare to the previous year?
In Q2 2025, Pulmonx's revenue increased by 21% to $45.9 million from $37.9 million in Q2 2024. However, the net loss also widened significantly, from $20.1 million in Q2 2024 to $25.3 million in Q2 2025, indicating higher operating expenses relative to revenue growth.
What is the significance of the increase in R&D expenses for Pulmonx?
The increase in R&D expenses to $18.9 million in Q2 2025 from $15.5 million in Q2 2024 signifies Pulmonx's ongoing commitment to innovation and product development. While this is crucial for long-term growth, it also contributes to the company's current net losses.
Risk Factors
- Sustained Net Losses and Accumulated Deficit [high — financial]: Pulmonx reported a net loss of $25.3 million for Q2 2025, an increase from $20.1 million in Q2 2024. The accumulated deficit grew to $459.0 million as of June 30, 2025, up from $433.7 million at March 31, 2025. This trend indicates ongoing operational challenges in achieving profitability.
- Declining Cash Position [medium — financial]: Cash and cash equivalents decreased to $189.0 million as of June 30, 2025, from $210.0 million at December 31, 2024. This represents a burn rate that requires careful management and potential future capital raises.
- Reliance on Single Product [high — operational]: The company's revenue is heavily dependent on the Zephyr Endobronchial Valve. Any disruption in the sales, manufacturing, or market acceptance of this key product could significantly impact financial performance.
- Need for Significant Capital [high — financial]: The growing accumulated deficit and cash burn highlight the company's ongoing need for substantial capital to fund operations, research and development, and commercialization efforts.
- Increased R&D Investment [medium — operational]: R&D expenses increased to $18.9 million for Q2 2025 from $15.5 million in the prior-year quarter. While necessary for innovation, this increased spending contributes to the net loss and requires careful monitoring of return on investment.
Industry Context
Pulmonx operates in the medical device sector, specifically focusing on treatments for severe lung disease. The industry is characterized by significant R&D investment, regulatory hurdles, and a need for clinical validation. Competition often comes from established players with broader product portfolios and from emerging technologies.
Regulatory Implications
As a medical device company, Pulmonx is subject to stringent regulatory oversight from bodies like the FDA. Compliance with manufacturing standards, clinical trial requirements, and post-market surveillance is critical. Any adverse regulatory actions could significantly impact product availability and market access.
What Investors Should Do
- Monitor R&D spending and pipeline progress.
- Analyze sales trends for the Zephyr Endobronchial Valve.
- Evaluate the company's cash burn rate and future financing needs.
Key Dates
- 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q, showing increased revenue but also a wider net loss and reduced cash reserves.
- 2025-04-01: Start of Second Quarter 2025 — Beginning of the reporting period for Q2 2025.
- 2024-06-30: End of Second Quarter 2024 — Prior year comparison period, showing lower revenue ($37.9M) and a smaller net loss ($20.1M).
- 2024-12-31: End of Fiscal Year 2024 — Previous year-end balance sheet comparison point for cash and cash equivalents ($210.0M).
Glossary
- Accumulated Deficit
- The cumulative net losses of a company that have not been offset by net income. It represents the total losses incurred since the company's inception. (Indicates the company's historical unprofitability and its ongoing need to generate profits to offset past losses.)
- Cash and Cash Equivalents
- Short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. (Represents the company's immediate liquidity and its ability to fund short-term obligations and operations.)
- Zephyr Endobronchial Valve
- Pulmonx's primary medical device for treating severe emphysema. (The core revenue-generating product for the company, making its performance critical.)
Year-Over-Year Comparison
Compared to the prior year's second quarter, Pulmonx has demonstrated strong revenue growth of 21%, reaching $45.9 million. However, this top-line improvement has been accompanied by a widening net loss, which increased from $20.1 million to $25.3 million. The company's cash reserves have also decreased from $210.0 million at the end of 2024 to $189.0 million as of June 30, 2025, indicating a higher cash burn rate.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 1, 2025 regarding Pulmonx Corp (LUNG).